A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

NCT02597049 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

424

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Dulaglutide
DRUG: Placebo
DRUG: SGLT2 inhibitor
DRUG: Metformin

Sponsor

Eli Lilly and Company